Article
The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.
Metabolism: clinical and experimental - 1 Jul 1993
Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J
Abstract excerpt
In a retrospective study, we examined the influence of apolipoprotein (apo) E polymorphism and gender on the response to treatment with 80 mg/d lovastatin in a homogeneous population of patients with familial hypercholesterolemia (FH), most of whom were carriers of the 10-kb deletion of the low-density lipoprotein (LDL) receptor gene. Apo E phenotype distribution among the 189 FH patients was not different from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.